

## Lytix Biopharma: Invitation to Q1 2025 Results Presentation

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its first quarter 2025 financial results on Thursday, May 15<sup>th</sup>, 2025.

Join us for a live webcast presentation featuring **CEO Øystein Rekdal** and **CFO Gjest Breistein**, where they will discuss the results and provide key insights. In addition, the newly elected Chair, **Eric Falcand**, will be introduced and he will share some of his views on the potential of Lytix's unique technology.

**Date:** Thursday, May 15<sup>th</sup>, 2025

**Time:** 11:15 AM CET

### **Q&A Session:**

We welcome your questions in advance. Please send them to [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com), and they will be addressed during the Q&A session following the presentation.

### **Webcast Details:**

The presentation and Q&A session will be conducted in English. You can view the live event by registering here: [https://channel.royalcast.com/landingpage/hegnarmedia/20250515\\_1/](https://channel.royalcast.com/landingpage/hegnarmedia/20250515_1/)

### **Missed the Live Session?**

A recording of the presentation will be available shortly after the event on our financial reports page: <https://www.lytixbiopharma.com/financial-reports>

### **For more information, please contact:**

Gjest Breistein, CFO

+47 952 60 512

[gjest.breistein@lytixbiopharma.com](mailto:gjest.breistein@lytixbiopharma.com)

### **About Lytix:**

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.